Share Your MM Story | DARZALEX® (daratumumab)

I want to share my story

* Required Field

First Name *

Last Name *

Email Address *

Phone Number *

I prefer to be contacted by* *

Phone

*Please select a preferred 30-minute window between 8:00 am and 8:00 pm ET for us to call

Start *

End

08:30 am

Yes, I would like to sign up to receive support and information about DARZALEX^®.

Yes, I would like to sign up to receive support and information during my DARZALEX® journey.

By providing your information, you are asking us to tell you more about the SHARE Network. The SHARE Network, a Janssen Global Services, LLC, program, will receive your information, and it will be shared with its affiliates and third parties involved in the SHARE Network in fulfillment of this and any optional requests. If at any time you decide to withdraw from SHARE Network communications, please call toll-free 1-855-369-1305 or email [email protected]. The information you provide may also be used by Janssen Biotech, Inc., the marketer of DARZALEX^®, and companies working on their behalf, including vendors and other affiliates, to fulfill your request and provide you with additional information and services from Janssen Biotech, Inc.

If you want to stop receiving this information or service, you may call 1-877-227-3728. All information you provide here will be governed by the Janssen Biotech, Inc., Privacy Policy, which can be found at darzalex.com/privacy-policy, and the SHARE Network Privacy Policy, which can be found at sharemyjanssenstory.com/privacy/. By providing your information and clicking the SUBMIT button, you are confirming that you have read, understand, and agree to these conditions.

Leave this field blank

Do not receive DARZALEX^® if you have a history of a severe allergic reaction to daratumumab or any of the ingredients in DARZALEX^®. See the ingredients for DARZALEX^® below.

What should I tell my healthcare provider before taking DARZALEX^®?

Before you receive DARZALEX^®, tell your healthcare provider about all of your medical conditions, including if you:

have a history of breathing problems.
have had shingles (herpes zoster).
are pregnant or plan to become pregnant. DARZALEX^® may harm your unborn baby.
- Females who are able to become pregnant should use an effective method of birth control during treatment and for at least 3 months after your final dose of DARZALEX^®. Talk to your healthcare provider about birth control methods that you can use during this time.
are breastfeeding or plan to breastfeed. It is not known if DARZALEX^® passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive DARZALEX^®?

DARZALEX^® may be given alone or together with other medicines used to treat multiple myeloma.
DARZALEX^® will be given to you by your healthcare provider by intravenous (IV) infusion into your vein.
Your healthcare provider will decide the time between doses as well as how many treatments you will receive.
Your healthcare provider will give you medicines before each dose of DARZALEX^® and after each dose of DARZALEX^® to help reduce the risk of infusion reactions.
If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.

What are the possible side effects of DARZALEX^®?

DARZALEX^® may cause serious reactions, including:

Infusion reactions. Infusion reactions are common with DARZALEX^® and can be severe or serious. Your healthcare provider may temporarily stop your infusion or completely stop treatment with DARZALEX^® if you have infusion reactions. Get medical help right away if you get any of the following symptoms:
- shortness of breath or trouble breathing
- dizziness or lightheadedness (hypotension)
- cough
- wheezing
- throat tightness
- runny or stuffy nose
- headache
- itching
- nausea
- vomiting
- chills
- fever
Changes in blood tests. DARZALEX^® can affect the results of blood tests to match your blood type. These changes can last for up to 6 months after your final dose of DARZALEX^®. Your healthcare provider will do blood tests to match your blood type before you start treatment with DARZALEX^®. Tell all of your healthcare providers that you are being treated with DARZALEX^® before receiving blood transfusions.
Decreases in blood cell counts. DARZALEX^® can decrease white blood cell counts which help fight infections and blood cells called platelets which help to clot blood. Your healthcare provider will check your blood cell counts during treatment with DARZALEX^®. Tell your healthcare provider if you develop fever or have signs of bruising or bleeding.

The most common side effects of DARZALEX^® include:

tiredness
nausea
diarrhea
shortness of breath
trouble sleeping
fever
cough
muscle spasms
back pain
joint pain
vomiting
cold-like symptoms (upper respiratory infection)
nerve damage causing tingling, numbness or pain
swollen hands, ankles or feet
constipation
chills
dizziness

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of DARZALEX^®. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of DARZALEX^®

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your healthcare provider or pharmacist for information about DARZALEX^® that is written for health professionals.

What are the ingredients in DARZALEX^®?
Active ingredient: daratumumab
Inactive ingredients: glacial acetic acid, mannitol, polysorbate 20, sodium acetate trihydrate, sodium chloride, and water for injection

Please see Important Product Information.

cp-60860v3

How Can We Help?

You are leaving the DARZALEX^® (daratumumab) website

You are leaving the DARZALEX^® (daratumumab) website

How Can We Help?

I want to share my story

You are leaving the DARZALEX® (daratumumab) website

You are leaving the DARZALEX® (daratumumab) website

You are leaving the DARZALEX^® (daratumumab) website

You are leaving the DARZALEX^® (daratumumab) website